1st Californian enrolls in Geron stem cell trial in spinal cord injuries

The Stanford University School of Medicine and the Santa Clara Valley Medical Center enrolled the first Californian — and fourth person overall — in a clinical trial using embryonic stem cells to treat recent spinal cord injuries.
The experimental treatment, developed by Menlo Park-based Geron Corp. (NASDAQ: GERN), is meant to test the safety of the cells in up to 10 people at seven trial sites in the United States. It is the first clinical study using cells from human embryonic stem cells approved by the Food and Drug Administration.